Clostridium difficile is a anaerobic, Gram-positive, spore-forming bacillus that can cause disease ranging from self-limiting diarrhoea to severe psudomembranous colitis. C. difficile infection commonly affects hospitalised patients and is increasingly identified in patients in the community. Antimicrobial treatment failures and patients with multiple recurrences have driven the search for new treatment options. This research study provided insights into the antimicrobial activity of several natural products against C. difficile, including effects on the spore cycle, activity and production of toxins, possible mechanisms of antibacterial action and in-vivo efficacy. Additional studies are warranted to further investigate the efficacy of these products.